AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

DNA · NYSE · Biotechnology

Ginkgo Bioworks (DNA)

Runs an automated cell-engineering foundry, selling R&D services, lab automation, and biological data to industry.

$9.39

After hours+0.04 (+0.47%)

At close$9.35(+17.17%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	55	35	38	56	89	44	48	50	39	33	19	20
Cost of revenue	7	7	9	14	10	10	12	15	13	−8	16	2
Gross profit	49	28	29	42	79	34	36	35	26	42	4	18
	335	206	207	265	134	138	125	100	116	112	75	77
Research & development	157	117	136	134	77	76	71	53	69	50	50	46
	82	89	70	66	52	57	49	43	45	46	38	31
General & administrative	82	89	70	66	52	57	49	43	45	46	38	31
Other expenses	96	0	0	65	5	4	5	4	2	16	−13	0
Operating income	−286	−178	−178	−223	−55	−104	−89	−66	−90	−71	−71	−59
	−17	−34	12	6	−2	−4	−2	5	9	−11	−5	1
Interest income	15	13	12	10	9	7	6	6	6	41	4	3
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−96	125	−12	−65	−3	56	−5	−4	−9	11	5	−2
Income before tax	−303	−212	−166	−217	−57	−108	−91	−61	−81	−81	−76	−57
Income tax expense	0	0	0	0	0	0	0	0	0	−1	0	0
Net income from continuing operations	−303	−212	−166	−217	−56	−108	−91	−60	−81	−81	−76	−57
Discontinued operations	0	0	0	0	0	0	0	0	0	0	−7	11
Net income	−303	−212	−166	−217	−56	−108	−91	−60	−81	−81	−83	−47
EPS, basic	−$6.21	−$4.28	−$3.32	−$4.23	−$1.08	−$2.07	−$1.68	−$1.10	−$1.45	−$1.43	−$1.39	−$0.75
EPS, diluted	−$6.21	−$4.31	−$3.32	−$4.23	−$1.08	−$2.07	−$1.68	−$1.10	−$1.45	−$1.43	−$1.39	−$0.75
Weighted average shares, basic	49	49	50	51	52	52	54	55	56	55	60	62
Weighted average shares, diluted	49	49	50	51	52	52	54	55	56	55	60	62
EBITDA	−169	−289	−153	−141	−35	−143	−68	−46	−67	−35	−63	−44
Depreciation & amortization	21	14	13	17	17	16	15	16	14	47	13	12
EBIT	−190	−303	−166	−158	−52	−159	−84	−62	−81	−81	−76	−57